Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver condition in Australia and worldwide and is often encountered in general practice.
The incidence of cirrhosis and hepatocellular carcinoma (HCC) related to MAFLD is increasing, and a standardised evidence-based approach is required for the identification and assessment of these patients.
This consensus statement details 21 evidence-based recommendations to aid primary care health professionals in the diagnosis and assessment of liver disease and comorbid conditions in patients with MAFLD. The application of these recommendations will aid in the determination of liver disease severity and assessment of underlying comorbid conditions in patients with MAFLD, thereby guiding appropriate referral pathways for specialist care and monitoring strategies.
The development of this document was led by experts in hepatology, general practice, endocrinology, cardiometabolic disease, clinical biochemistry, nursing, implementation science and public health, with review by consumer representatives. The consensus manuscript was available for public consultation in July 2024.
Review and endorsement:
Representatives from the following organisations contributed to the development of the MAFLD consensus statement.
These organisations have had the opportunity to review and endorse the clinical resource:
GP Education Activities (free of charge, CPD accredited):
Presented by Prof Leon Adams (Co-Chair of the Gastroenterological Society of Australia MAFLD Consensus Statement Project) and Dr Gary Deed (Chair, RACGP Specific Interests Diabetes), this webinar outlines what the new evidence-based recommendations are and explores how GPs can apply them to a clinical pathway for their patients.
University of Sydney GP Education Program: A free nationwide education program for assessment and management including specialist referral of patients with MAFLD in Australian general practice.
Co-designed/delivered by GPs and specialists
Evidence-based and up-to-date clinical information
The overall goal is to address the current gaps in patient care by educating general practitioners across Australia about the diagnostic challenges for MAFLD using evidence-based clinical guidelines and the provision of healthcare pathways for the prevention and management of this condition.
Self-paced, bite sized and problem based e-learning modules
GESA is a not-for-profit organisation
3/517 Flinders Lane
Melbourne VIC 3000 Australia
Email: gesa@gesa.org.au
Phone: 1300 766 176
ABN: 44 001 171 115
GESA's business hours are 8:30am - 5:30pm Monday to Friday. The office will be closed on Victorian and national public holidays.
GESA is an ACNC-registered health-promotion charity with 'deductible gift recipient' status
For all course, event and stakeholder engagement inquiries contact us at gesa@gesa.org.au or on 1300 766 176.
For all media and social media inquiries please contact the GESA Communications Team at mediaenquiry@gesa.org.au or on1300 766 176.
For membership information please contact the GESA Membership Team at memberservices@gesa.org.au or on
1300 766 176.
Images used on this site may include stock photos and the associated information may not represent the personal situation, views or beliefs of the people in the images.